FLT1 and melanoma: Interestingly, VEGFR‐1 blockade by D16F7 mAb reduces ECM invasion triggered by VEGF‐A and PlGF, supporting the hypothesis that up‐regulation of VEGFR‐1 might contribute to tumour progression and spreading of melanoma after acquisition of a drug‐resistant phenotype.